TITLE:
Evaluation of the Effect on Glucose Control and the Safety and Tolerability of AC2993 in Patients With Type 2 Diabetes Mellitus

CONDITION:
Diabetes Mellitus, Non-Insulin-Dependent

INTERVENTION:
Placebo 0.01 mL

SUMMARY:

      This is a multicenter, randomized, blinded, placebo-controlled, short-term, dose-response
      study to examine the effects on glucose control of AC2993 as compared to placebo in patients
      with type 2 diabetes. Patients will be individuals with type 2 diabetes treated with
      metformin for at least 3 months prior to screening. Patients whose diabetes management
      consists of diet and exercise will also be eligible for this study.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 18 Years to 65 Years
Criteria:

        Inclusion Criteria:

          -  Subjects with type 2 diabetes

          -  Treated with diet and exercise alone or with metformin for at least 3 months prior to
             screening

          -  BMI 27-45 kg/m^2

          -  HbA1c between 7.0 % and 8.0 %

        Exclusion Criteria:

          -  Treated with other oral anti-diabetic agents other than metformin within 3 months of
             screening

          -  Patients previously treated with AC2993

          -  Patients presently treated with insulin
      
